期刊文献+

LC-MS/MS法测定犬体内托拉塞米浓度及相对生物利用度研究 被引量:2

LC-MS/MS determination of torasemide in Beagle dog plasma and bioavailability evaluation
下载PDF
导出
摘要 目的:建立LC-MS/MS法测定Beagle犬体内托拉塞米的浓度,并研究托拉塞米缓释片的相对生物利用度。方法:色谱柱为Waters Sym-metry-C18(100mm×4.6mm,5μm);流动相为甲醇∶20mmol/L甲酸铵(65∶35,V∶V);流速0.4mL/min;柱温30℃。采用两制剂双周期随机交叉试验设计,分别给予6只Beagle犬受试制剂或参比制剂5mg,采用LC-MS/MS法测定给药后不同时间的血药浓度。结果:托拉塞米线性范围为0.02~5μg/mL,最低定量限为0.02μg/mL,分析方法灵敏、稳定、特异性高。受试制剂和参比制剂的主要药动学参数:峰浓度(Cmax)、达峰时间(tmax)和药-时曲线下面积(AUC0-48h)分别为(2.6±0.5)g/mL和(3.0±0.6)g/mL、(3.3±1.4)h和(1.2±0.8)h、(36.1±11.0)g.h.mL-1和(32.1±13.1)g.h.mL-1。以AUC0-48h计算,受试制剂的相对生物利用度F为(118.0±28.3)%。结论:该方法操作简单、准确、重复性好,并成功地运用于犬体内托拉塞米相对生物利用度的研究。 AIM. To establish an LC-MS/MS method for the determination of torasemide in Beagle dog plasma, and study the relative bio- availability of the torasemide sustained release tablets. METHODS: A reversed phase HPLC column of Waters Symmetry-C18 (100 mm × 4. 6 mm, 5 μm) was used in the experiment. Aceto- nitrile-20 mmol/L ammonium formate (65 : 35, V/V) was used as mobile phase at the flow rate of 0.4 mL/min, the column temperature was set at 30 ℃. A single oral dose of 5 mg torasemide release tablets or reference tablets were given to Beagle dogs in an open randomized two way rossover design. The concentrations of plasma ;amples collected at the different time were deermined by LC-MS/MS method. RESULTS: Vith the linear range of 0.02--5 μg/mL and the )wet limit quantification of 0.02 μg/mL, the ,C-MS/MS method had high sensitivity, stability and specificity. The main pharmacokinenc pa rameters of test sustained release tablets and ref- erence tablets were as follows-the Cmax were (2.6±0.5) μg/mL and (3.0±0.6) g/mL,the t were (3.3 ± 1.4) h and ( 1.2 ±0.8) h, the AUC0 48hwere (36.1±11.0) μg· h· mL^-1 ancl (32.1±13.1) μg· h· mL^-1. Compared to reg- ular tablets, the bioavailability of sustained release tablets was (118.0±28.3)Y00. CONCLUSION: The method is simple, accurate and robust for the determination o{ torasemide in Beagle dog plasma, and successfully applied it to the bioavailahility evaluation of torasemide sustained release tablets given to Beagle dogs.
出处 《中国临床药理学与治疗学》 CAS CSCD 2012年第2期199-205,共7页 Chinese Journal of Clinical Pharmacology and Therapeutics
基金 国家973项目(2010CB735602)
关键词 托拉塞米 LC-MS/MS 相对生物利用度 Torasemide LC-MS/ MS .Rela-tive bioavailability
  • 相关文献

参考文献14

  • 1Knauf H,Mutschle E.Clinical pharmacokineticsand pharmacodynamics of torasemide[J].ClinPharmacokinet,1998,34(1):1-24.
  • 2Cuvelier R,Pellegrin P,Lesen M,et al.Site of ac-tion of torasemide in man[J].Eur J Clin Phama-col,1986,31:15-19.
  • 3Brater DC.Clinical pharmacology of loop diuretics[J].Drugs,1991,41:14-22.
  • 4Akesolo U,González L,Jiménez RM,et al.Multi-variate optimisation of a cyclodextrin-assisted-cap-illary zone electrophoretic method for the separa-tion of torasemide and its metabolites[J].J Chro-matogr A,2003,990(1/2):271-279.
  • 5Engelhardt S,Meineke I,Brockmller J.Improvedsolid-phase extraction and HPLC measurement oftorasemide and its important metabolites[J].JChromatogr B Analyt Technol Biomed Life Sci,2006,831(1/2):31-35.
  • 6March C,Farthing D,Wells B,et al.Solid-phaseextraction and liquid chromatography of torsemide[torasemide]and metabolites from plasma and u-rine[J].Pharm Sci,1990,79(5):453-457.
  • 7Imran K,Punnamchand L,Natvarlal SM.A simplesample preparation with HPLC-UV method for es-timation of tiropramide from plasma:application tobioequivalence study[J].J Pharm Biomed Anal,2007,43(3):1135-1140.
  • 8Liu K,Lee YK,Ryu JY,et al.Simple and SensitiveAssay of Torasemide in Human Plasma by High-Performance Liquid Chromatography Using aMonolithic Silica Column[J].Chromatographia,2008,60(12):639-643.
  • 9Khan IJ,Loya P,Saraf MN.A Simplified HPLCMethod for Quantification of Torsemide from Hu-man Plasma and its Application to a Bioequivalence[J].Study Indian Pharm Sci,2008,70(4):519-522.
  • 10周燕文,兰聪贤,刘倩,苏明.托拉塞米胶囊与片剂在健康人体内的药动学和生物等效性[J].中国医院药学杂志,2008,28(1):24-27. 被引量:4

二级参考文献32

  • 1刘惠侠.长效袢利尿药托拉塞米临床研究进展[J].世界临床药物,2004,25(8):495-498. 被引量:11
  • 2蒋文,李一石,黄一玲,田蕾,黄岩,刘晗,苏绮,王蓓,成小如,姚康宝,华潞,张阴凤.托拉塞米片的正常人体药动学研究[J].中国新药杂志,2004,13(9):828-831. 被引量:7
  • 3况扶华,华潞,田蕾,黄一玲,黄岩,刘晗,苏绮,王蓓,成小如,张阴凤,李一石.托拉塞米片多次给药药动学研究[J].中国药学杂志,2005,40(9):693-695. 被引量:7
  • 4[1]Greger R.Inhibition of active NaCl reabsorption in the thick ascending limb of the loop of Henle by torasemide[J].Arzneimittelforsch,1988,38(1A):151-152.
  • 5[2]Cuvelier R,Pellegrin P,Lesen M,et al.Site of action of torasemide in man[J].Eur J Clin Phamacol,1986,31(Suppl):S15-S19.
  • 6[3]Brater DC.Clinical pharmacology of loop diuretics[J].Drugs,1991,41(Supp 3):S14-S22.
  • 7[4]Knauf H,Mutschler E.Clinical pharmacokinetics and pharmacodynamics of torasemide[J].Clin Pharmacokinet,1998,34(1):1-24.
  • 8[5]Lesne M.Comparison of the pharmacokinetics and pharmacodynamics of torasemide and furosemide in healthy volunteers[J].Arzneimittelforsch,1988,38(1A):160-163.
  • 9[6]Friedel HA,Buckley MMT.Torasemide-a review of its pharmacology,properties and therapeutic potential[J].Drugs,1991,41(1):81-103.
  • 10[7]Neugebauer G,Besenfelder E,Von Moellendorff E.Pharmacokinetics and metabolism of torasemide in man[J].Arzneimittelforsch,1988,38(1):164-166.

共引文献17

同被引文献31

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部